Ligand Completes Acquisition of Icagen Core Assets, Partnered Programs and Ion Channel Technologies

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the completion of its acquisition of the core assets of Icagen’s North Carolina operations. As previously announced, the purchase price was $15 million in cash, and Icagen is entitled to receive additional cash payments based on certain revenue achievements. “We are very pleased to add the Icagen technologies, partnerships and this profitable business to Ligand,” said John Higgins, Chief Executive Officer of Ligand. “We all know how extremely challenging the current business environment is, and I want to commend the teams on both sides who worked together to get this deal done. It’s a fantastic acquisition that will enable Ligand to expand its services to current partners and drive new collaborations.”

Read the full article: Ligand Completes Acquisition of Icagen Core Assets, Partnered Programs and Ion Channel Technologies //

Source: https://www.businesswire.com/news/home/20200402005742/en/Ligand-Completes-Acquisition-Icagen-Core-Assets-Partnered

Scroll to Top